MY160064A - Benzoxazepin pi3k inhibitor compounds and methods of use - Google Patents
Benzoxazepin pi3k inhibitor compounds and methods of useInfo
- Publication number
- MY160064A MY160064A MYPI2012000823A MYPI2012000823A MY160064A MY 160064 A MY160064 A MY 160064A MY PI2012000823 A MYPI2012000823 A MY PI2012000823A MY PI2012000823 A MYPI2012000823 A MY PI2012000823A MY 160064 A MY160064 A MY 160064A
- Authority
- MY
- Malaysia
- Prior art keywords
- methods
- inhibitor compounds
- pi3k inhibitor
- benzoxazepin
- compounds
- Prior art date
Links
- ZCXLTWVZYXBHJS-UHFFFAOYSA-N 1,2-benzoxazepine Chemical compound O1N=CC=CC2=CC=CC=C12 ZCXLTWVZYXBHJS-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 239000012828 PI3K inhibitor Substances 0.000 title 1
- 229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1
- -1 PYRAZOLYL Chemical group 0.000 abstract 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
- 230000001093 anti-cancer Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24638109P | 2009-09-28 | 2009-09-28 | |
| US33068510P | 2010-05-03 | 2010-05-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY160064A true MY160064A (en) | 2017-02-15 |
Family
ID=43037239
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2012000823A MY160064A (en) | 2009-09-28 | 2010-09-27 | Benzoxazepin pi3k inhibitor compounds and methods of use |
| MYPI2015002473A MY184074A (en) | 2009-09-28 | 2010-09-27 | Benzoxazepin p13k inhibitors compounds and methods of use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2015002473A MY184074A (en) | 2009-09-28 | 2010-09-27 | Benzoxazepin p13k inhibitors compounds and methods of use |
Country Status (31)
| Country | Link |
|---|---|
| US (7) | US8242104B2 (enExample) |
| EP (3) | EP2483278B1 (enExample) |
| JP (2) | JP5540101B2 (enExample) |
| KR (1) | KR101428346B1 (enExample) |
| CN (2) | CN104744491B (enExample) |
| AR (1) | AR078187A1 (enExample) |
| AU (1) | AU2010299816C1 (enExample) |
| BR (1) | BR112012006807A2 (enExample) |
| CA (1) | CA2772691C (enExample) |
| CL (1) | CL2012000754A1 (enExample) |
| CO (1) | CO6491026A2 (enExample) |
| CR (1) | CR20120121A (enExample) |
| DK (1) | DK2483278T3 (enExample) |
| EC (1) | ECSP12011755A (enExample) |
| ES (2) | ES2570569T3 (enExample) |
| HR (1) | HRP20140229T1 (enExample) |
| IL (2) | IL217558A (enExample) |
| MA (1) | MA33531B1 (enExample) |
| MX (1) | MX2012003591A (enExample) |
| MY (2) | MY160064A (enExample) |
| NZ (1) | NZ597833A (enExample) |
| PE (1) | PE20121025A1 (enExample) |
| PL (1) | PL2483278T3 (enExample) |
| PT (1) | PT2483278E (enExample) |
| RS (1) | RS53164B (enExample) |
| RU (2) | RU2600927C2 (enExample) |
| SG (1) | SG10201405049RA (enExample) |
| SI (1) | SI2483278T1 (enExample) |
| TW (1) | TWI423980B (enExample) |
| WO (1) | WO2011036280A1 (enExample) |
| ZA (1) | ZA201202199B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8952034B2 (en) | 2009-07-27 | 2015-02-10 | Gilead Sciences, Inc. | Fused heterocyclic compounds as ion channel modulators |
| PE20140918A1 (es) * | 2009-09-28 | 2014-08-06 | Hoffmann La Roche | Compuestos de benzoxepina inhibidores de la pi3k |
| RU2600927C2 (ru) * | 2009-09-28 | 2016-10-27 | Ф.Хоффманн-Ля Рош Аг | Бензоксазепиновые ингибиторы pi3k и способы применения |
| EA026385B9 (ru) | 2010-07-02 | 2017-08-31 | Джилид Сайэнс, Инк. | Конденсированные гетероциклические соединения в качестве модуляторов ионных каналов |
| RU2013143747A (ru) * | 2011-03-21 | 2015-04-27 | Ф. Хоффманн-Ля Рош Аг | Соединения бензоксазепина, селективные в отношении pi3k p110 дельта и способы их применения |
| CN105693645B (zh) | 2011-05-10 | 2018-10-09 | 吉利德科学公司 | 作为离子通道调节剂的稠合杂环化合物 |
| WO2012156379A1 (en) | 2011-05-13 | 2012-11-22 | Universität Zürich | PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING |
| TWI549944B (zh) | 2011-07-01 | 2016-09-21 | 吉李德科學股份有限公司 | 作為離子通道調節劑之稠合雜環化合物 |
| NO3175985T3 (enExample) * | 2011-07-01 | 2018-04-28 | ||
| BR112014019209A2 (pt) | 2012-02-17 | 2017-07-04 | Hoffmann La Roche | compostos tricíclicos e métodos de uso para os mesmos |
| EP2858666B1 (en) | 2012-06-08 | 2019-09-04 | F.Hoffmann-La Roche Ag | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer |
| EP2872161B1 (en) | 2012-06-26 | 2020-12-16 | Del Mar Pharmaceuticals | Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations |
| CN102775395A (zh) * | 2012-07-12 | 2012-11-14 | 江苏七洲绿色化工股份有限公司 | 一种丙环唑的制备方法及丙环唑中间体 |
| ES2608628T3 (es) * | 2012-08-07 | 2017-04-12 | Janssen Pharmaceutica Nv | Procedimiento para la preparacion de derivados de ester heterociclicos |
| WO2014140073A1 (en) * | 2013-03-13 | 2014-09-18 | F. Hoffmann-La Roche Ag | Process for making benzoxazepin compounds |
| AU2014251038A1 (en) | 2013-04-08 | 2015-11-26 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| KR20180093138A (ko) | 2013-12-16 | 2018-08-20 | 에프. 호프만-라 로슈 아게 | 2-(4-(2-(1-이소프로필-3-메틸-1H-1,2,4-트라이아졸-5-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)-1H-피라졸-1-일)-2-메틸프로판아미드의 다형체, 이의 제조 방법 및 이의 약학적 용도 |
| CA2940576A1 (en) | 2014-03-13 | 2015-09-17 | F. Hoffmann-La Roche Ag | Therapeutic combinations with estrogen receptor modulators |
| AR103598A1 (es) | 2015-02-02 | 2017-05-24 | Forma Therapeutics Inc | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac |
| AU2016215432B2 (en) | 2015-02-02 | 2020-07-30 | Valo Early Discovery, Inc. | 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors |
| AR104068A1 (es) | 2015-03-26 | 2017-06-21 | Hoffmann La Roche | Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer |
| ES2770128T3 (es) * | 2015-04-30 | 2020-06-30 | Recordati Ag | Derivados de pirazol tricíclicos condensados útiles para modular los receptores farnesoide x |
| AU2016278040B2 (en) | 2015-06-16 | 2019-07-04 | Nanophagix LLC | Drug delivery and imaging chemical conjugate, formulations and methods of use thereof |
| AU2016287189A1 (en) | 2015-06-29 | 2017-10-12 | F. Hoffmann-La Roche Ag | Methods of treatment with taselisib |
| JP6522807B2 (ja) * | 2015-07-02 | 2019-05-29 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベンゾオキサゼピンオキサゾリジノン化合物及び使用方法 |
| CN112047960B (zh) * | 2015-07-02 | 2024-08-02 | 豪夫迈·罗氏有限公司 | 苯并氧氮杂䓬噁唑烷酮化合物及其使用方法 |
| US10065970B2 (en) | 2015-09-08 | 2018-09-04 | Genentech, Inc. | Tricyclic PI3K inhibitor compounds and methods of use |
| US9721369B2 (en) * | 2015-09-15 | 2017-08-01 | Facebook, Inc. | Systems and methods for utilizing multiple map portions from multiple map data sources |
| EP3472131B1 (en) | 2016-06-17 | 2020-02-19 | Forma Therapeutics, Inc. | 2-spiro-5- and 6-hydroxamic acid indanes as hdac inhibitors |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| JP2019530688A (ja) | 2016-09-29 | 2019-10-24 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | 新規５−置換イミダゾリルメチル誘導体 |
| KR102537048B1 (ko) * | 2016-12-15 | 2023-05-26 | 에프. 호프만-라 로슈 아게 | (S)-2-((2-((S)-4-(다이플루오로메틸)-2-옥소옥사졸리딘-3-일)-5,6-다이하이드로벤조[f]이미다조[1,2-d][1,4]옥사제핀-9-일)아미노) 프로판아미드의 제조 방법 |
| ES2969041T3 (es) | 2017-03-02 | 2024-05-16 | Genentech Inc | Tratamiento adyuvante del cáncer de mama positivo para HER2 |
| TWI826373B (zh) * | 2017-04-28 | 2023-12-21 | 瑞士商赫孚孟拉羅股份公司 | (s)-2-((2-((s)-4-(二氟甲基)-2-氧代唑烷-3-基)-5,6-二氫苯并[f]咪唑并[1,2-d][1,4]氧氮呯-9-基)胺基)丙醯胺之多晶型及固體形式及製造方法 |
| EP3700530B1 (en) * | 2017-10-26 | 2023-04-19 | Xynomic Pharmaceuticals, Inc. | Crystalline salts of a b-raf kinase inhibitor |
| CN114835729B (zh) * | 2018-05-30 | 2024-05-31 | 江苏豪森药业集团有限公司 | 含三并环类衍生物抑制剂、其制备方法和应用 |
| CN111909157B (zh) * | 2019-05-07 | 2023-02-03 | 南京药石科技股份有限公司 | Ezh2抑制剂及其用途 |
| WO2021088845A1 (zh) * | 2019-11-04 | 2021-05-14 | 贝达药业股份有限公司 | 咪唑烷酮类化合物及其制备方法与应用 |
| CN118084935A (zh) * | 2019-11-04 | 2024-05-28 | 贝达药业股份有限公司 | 咪唑烷酮类化合物及其制备方法与应用 |
| AU2020389670A1 (en) * | 2019-11-25 | 2022-05-19 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Three fused ring derivative-containing salt or crystal form and pharmaceutical composition thereof |
| JP7652935B2 (ja) * | 2021-05-03 | 2025-03-27 | 山東軒竹医薬科技有限公司 | 三環式ユビキチン特異的プロテアーゼ１阻害剤及びその使用 |
| MX2023013305A (es) * | 2021-05-13 | 2024-01-31 | Betta Pharmaceuticals Co Ltd | Compuesto polimorfo de imidazolidinona, método de preparación del mismo y uso del mismo. |
| EP4347574A1 (en) | 2021-05-28 | 2024-04-10 | Genentech, Inc. | Process for the preparation of benzoxazepin oxazolidinone compounds |
| CN120202205A (zh) * | 2022-11-17 | 2025-06-24 | 微境生物医药科技(上海)有限公司 | 三并环类PI3Kα抑制剂及其制备方法和医药用途 |
| CN116003280B (zh) * | 2022-12-30 | 2024-11-19 | 合肥工业大学 | 一种芳基甲酰胺类化合物的光化学合成方法 |
| WO2025082533A1 (zh) * | 2023-10-21 | 2025-04-24 | 上海轶诺药业有限公司 | 一种稠环化合物及其制备和应用 |
| WO2025237374A1 (zh) * | 2024-05-16 | 2025-11-20 | 微境生物医药科技(上海)有限公司 | PI3Kα抑制剂及其制备方法和医药用途 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| GB8504702D0 (en) | 1985-02-23 | 1985-03-27 | Zyma Sa | Tricyclic compounds |
| US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
| FR2677356B1 (fr) | 1991-06-05 | 1995-03-17 | Sanofi Sa | Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant. |
| KR0126300B1 (ko) | 1992-12-28 | 1997-12-26 | 나이토 하루오 | 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체 |
| AU678503B2 (en) * | 1993-09-24 | 1997-05-29 | Takeda Chemical Industries Ltd. | Condensed heterocyclic compounds and their use as squalene synthetase inhibitors |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
| AU1272597A (en) | 1995-11-17 | 1997-06-11 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
| US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
| DE19908535A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen Thiazol-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| DE19908533A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische Thiazol-Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE19908538A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen |
| DE19908537A1 (de) | 1999-02-26 | 2000-08-31 | Aventis Pharma Gmbh | Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas |
| US7273880B2 (en) | 1999-06-30 | 2007-09-25 | H. Lunbeck A/S | Selective NPY (Y5) antagonists |
| AU2001246494A1 (en) | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| PL367534A1 (en) | 2001-02-02 | 2005-02-21 | Schering Corporation | 3,4-di-substituted cyclobutene-1, 2-diones as cxc chemokine receptor antagonists |
| TWI232863B (en) * | 2001-06-11 | 2005-05-21 | Akzo Nobel Nv | Benzoxazepine derivatives |
| US20040082602A1 (en) | 2002-07-19 | 2004-04-29 | Hagen Timothy J. | Substituted thiophene carboxamide compounds for the treatment of inflammation |
| MXPA05008400A (es) * | 2003-02-07 | 2005-10-05 | Warner Lambert Co | Derivados de oxazolidinona n-sustituidos por un anillo triciclico, para su uso como agentes antibacterianos. |
| TW200510356A (en) * | 2003-08-01 | 2005-03-16 | Takeda Chemical Industries Ltd | Benzoxaepine compounds |
| US20050239767A1 (en) | 2003-10-28 | 2005-10-27 | Chan Michael K | Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands |
| KR20070039885A (ko) * | 2004-07-01 | 2007-04-13 | 머크 앤드 캄파니 인코포레이티드 | 유사분열 키네신 억제제 |
| US20060106013A1 (en) | 2004-10-07 | 2006-05-18 | Boehringer Ingelheim International Gmbh | PI3-kinases |
| ATE504565T1 (de) | 2005-10-07 | 2011-04-15 | Exelixis Inc | Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| US20070238718A1 (en) * | 2006-04-06 | 2007-10-11 | Matthias Grauert | Thiazolyl-dihydro-indazole |
| GB0610866D0 (en) * | 2006-06-02 | 2006-07-12 | Hammersmith Imanet Ltd | Novel in vivo imaging compounds |
| WO2008014483A1 (en) * | 2006-07-28 | 2008-01-31 | Alcan Packaging Flexible France | Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva) |
| AU2007281911B2 (en) | 2006-08-04 | 2014-02-06 | Beth Israel Deaconess Medical Center | Inhibitors of pyruvate kinase and methods of treating disease |
| US8779154B2 (en) | 2006-09-26 | 2014-07-15 | Qinglin Che | Fused ring compounds for inflammation and immune-related uses |
| PT2439205E (pt) * | 2006-12-29 | 2015-07-16 | Abbvie Deutschland | Compostos de carboxamida e seus usos como inibidores de calpaína |
| US8101740B2 (en) | 2007-09-19 | 2012-01-24 | The Regents Of The University Of California | Positron emission tomography probes for imaging immune activation and selected cancers |
| WO2009123971A1 (en) | 2008-03-31 | 2009-10-08 | Genentech, Inc. | Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use |
| WO2010043676A1 (en) * | 2008-10-17 | 2010-04-22 | Boehringer Ingelheim International Gmbh | Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor |
| PE20140918A1 (es) * | 2009-09-28 | 2014-08-06 | Hoffmann La Roche | Compuestos de benzoxepina inhibidores de la pi3k |
| RU2600927C2 (ru) * | 2009-09-28 | 2016-10-27 | Ф.Хоффманн-Ля Рош Аг | Бензоксазепиновые ингибиторы pi3k и способы применения |
-
2010
- 2010-09-27 RU RU2012117398/04A patent/RU2600927C2/ru active
- 2010-09-27 RS RS20140060A patent/RS53164B/sr unknown
- 2010-09-27 DK DK10757213.3T patent/DK2483278T3/da active
- 2010-09-27 AR ARP100103491A patent/AR078187A1/es unknown
- 2010-09-27 HR HRP20140229AT patent/HRP20140229T1/hr unknown
- 2010-09-27 MY MYPI2012000823A patent/MY160064A/en unknown
- 2010-09-27 ES ES13193562T patent/ES2570569T3/es active Active
- 2010-09-27 EP EP10757213.3A patent/EP2483278B1/en active Active
- 2010-09-27 TW TW099132661A patent/TWI423980B/zh active
- 2010-09-27 JP JP2012530282A patent/JP5540101B2/ja active Active
- 2010-09-27 MY MYPI2015002473A patent/MY184074A/en unknown
- 2010-09-27 MX MX2012003591A patent/MX2012003591A/es active IP Right Grant
- 2010-09-27 AU AU2010299816A patent/AU2010299816C1/en active Active
- 2010-09-27 PE PE2012000390A patent/PE20121025A1/es active IP Right Grant
- 2010-09-27 ES ES10757213.3T patent/ES2444779T3/es active Active
- 2010-09-27 CN CN201510043641.XA patent/CN104744491B/zh active Active
- 2010-09-27 PL PL10757213T patent/PL2483278T3/pl unknown
- 2010-09-27 SI SI201030536T patent/SI2483278T1/sl unknown
- 2010-09-27 PT PT107572133T patent/PT2483278E/pt unknown
- 2010-09-27 KR KR1020127010974A patent/KR101428346B1/ko active Active
- 2010-09-27 RU RU2016105810A patent/RU2654068C1/ru active
- 2010-09-27 CN CN201080053938.XA patent/CN102762576B/zh active Active
- 2010-09-27 EP EP20140190276 patent/EP2845592A1/en not_active Withdrawn
- 2010-09-27 SG SG10201405049RA patent/SG10201405049RA/en unknown
- 2010-09-27 EP EP13193562.9A patent/EP2711368B1/en active Active
- 2010-09-27 CA CA2772691A patent/CA2772691C/en active Active
- 2010-09-27 BR BR112012006807-5A patent/BR112012006807A2/pt not_active Application Discontinuation
- 2010-09-27 WO PCT/EP2010/064208 patent/WO2011036280A1/en not_active Ceased
- 2010-09-27 US US12/890,812 patent/US8242104B2/en active Active
- 2010-09-27 NZ NZ597833A patent/NZ597833A/en unknown
-
2012
- 2012-01-10 CO CO12002995A patent/CO6491026A2/es active IP Right Grant
- 2012-01-16 IL IL217558A patent/IL217558A/en active IP Right Grant
- 2012-02-15 MA MA34637A patent/MA33531B1/fr unknown
- 2012-03-13 CR CR20120121A patent/CR20120121A/es unknown
- 2012-03-26 ZA ZA2012/02199A patent/ZA201202199B/en unknown
- 2012-03-27 CL CL2012000754A patent/CL2012000754A1/es unknown
- 2012-03-28 EC ECSP12011755 patent/ECSP12011755A/es unknown
- 2012-05-22 US US13/477,587 patent/US8343955B2/en active Active
- 2012-11-20 US US13/681,763 patent/US8586574B2/en active Active
-
2013
- 2013-10-07 US US14/047,206 patent/US8785626B2/en active Active
- 2013-11-01 JP JP2013228826A patent/JP5625101B2/ja active Active
-
2014
- 2014-06-05 US US14/297,142 patent/US9198918B2/en active Active
-
2015
- 2015-05-28 IL IL239081A patent/IL239081B/en active IP Right Grant
- 2015-11-03 US US14/930,929 patent/US9546178B2/en active Active
-
2016
- 2016-12-05 US US15/368,937 patent/US9670228B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY160064A (en) | Benzoxazepin pi3k inhibitor compounds and methods of use | |
| WO2009016460A8 (en) | Pyrazole compounds and their use as raf inhibitors | |
| MX2011012520A (es) | Compuestos inhibidores de pi3k de pirimidina biciclicos selectivos para p110 delta y metodos de uso de los mismos. | |
| MY170823A (en) | Protein kinase inhibitors | |
| EA024194B8 (ru) | Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы | |
| MX340013B (es) | Compuestos de benzoxazepina selectivos para fosfatidilinositol 3-cinasa (pi3k) p110 delta y metodos de uso. | |
| NZ602271A (en) | Bicyclic compounds and their uses as dual c-src / jak inhibitors | |
| MA32272B1 (fr) | Inhibiteurs de raf de pyrazole [3,4-b]pyridine | |
| PH12013501243A1 (en) | Tricyclic pi3k inhibitor compounds and methods of use | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| PH12012501864A1 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| WO2010088050A3 (en) | Bicyclic pyrazolo-heterocycles | |
| CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
| MX2010009739A (es) | Inhibidores de cinasa pim y metodos para su uso. | |
| UA108926C2 (ru) | LibreOffice? [2,3-D] +" +" !+ | |
| ATE543811T1 (de) | Pyridazinderivate als faktor-xia-inhibitoren | |
| MX2012002876A (es) | Derivados de dihidropteridinona, proceso para su preparacion y uso farmaceutico. | |
| MX342440B (es) | Derivados fluorados de aminotriazol. | |
| MX349551B (es) | Proceso para preparar compuestos tienopirimidinas. | |
| PH12012501643A1 (en) | Pyrazolopyrimidine compounds and their use as pde 10 inhibitors | |
| EP4534148A3 (en) | Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production | |
| WO2011041304A3 (en) | Antimalarial agents that are inhibitors of dihydroorotate dehydrogenase | |
| MY155829A (en) | Pyrazole derivatives, preparation thereof and therapeutic use thereof | |
| WO2010123545A3 (en) | Angiogenesis inhibitors | |
| WO2013190123A8 (en) | Pyrimidinone derivatives as antimalarial agents |